RAPT Therapeutics Board Unanimously Recommends Shareholders Accept GSK's $58.00 All-Cash Tender Offer
RAPT has more than doubled off its 52-week low of $5.665.
Summary
RAPT Therapeutics' Board of Directors unanimously recommends shareholders accept GSK's $58.00 per share all-cash tender offer, citing a significant premium and transaction certainty.
Key Events · M&A and Partnerships · RAPT
-
Board Recommends Tender Offer
The Board of Directors unanimously determined that GSK's $58.00 per share all-cash tender offer is advisable, fair, and in the best interests of the company and its stockholders, recommending they tender their shares.
-
Significant Acquisition Premium
The $58.00 per share offer price represents a compelling premium, including approximately 65% over the closing price on January 16, 2026, and 58% over the 52-week high prior to the merger agreement.
-
All-Cash Transaction Provides Certainty
The all-cash consideration offers immediate liquidity and certainty of value to shareholders, mitigating risks associated with RAPT's standalone operations, clinical development, and future financing needs.
-
Tender Offer Commencement and Expiration
The tender offer formally commenced on February 2, 2026, and is set to expire on March 2, 2026, unless extended.
Analysis · RAPT · Life Sciences
RAPT Therapeutics' Board of Directors has formally recommended that shareholders tender their shares in response to GSK's commenced tender offer to acquire the company for $58.00 per share in cash. This filing provides the detailed rationale for the Board's unanimous recommendation, highlighting the significant premium offered and the certainty of an all-cash transaction. The offer price represents a substantial premium over recent trading prices, including a 65% premium to the closing price on January 16, 2026, and a 58% premium to the 52-week high prior to the merger agreement. This definitive acquisition by a major pharmaceutical company like GSK is a thesis-altering event for RAPT Therapeutics, providing immediate liquidity and a favorable exit for shareholders, especially given the inherent risks and capital requirements of a standalone biotechnology company.
At the time of this filing, RAPT was trading at $57.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.67 to $57.80. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.